XTX Topco Ltd Takes $581,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

XTX Topco Ltd bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 6,924 shares of the biopharmaceutical company's stock, valued at approximately $581,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Zacks Investment Management grew its stake in shares of Gilead Sciences by 9.8% in the third quarter. Zacks Investment Management now owns 369,358 shares of the biopharmaceutical company's stock valued at $30,967,000 after buying an additional 33,099 shares in the last quarter. Zega Financial LLC acquired a new stake in shares of Gilead Sciences in the third quarter valued at about $507,000. Zurich Insurance Group Ltd FI grew its stake in shares of Gilead Sciences by 791.5% in the third quarter. Zurich Insurance Group Ltd FI now owns 273,685 shares of the biopharmaceutical company's stock valued at $22,946,000 after buying an additional 242,985 shares in the last quarter. Goldstream Capital Management Ltd acquired a new stake in shares of Gilead Sciences in the third quarter valued at about $104,000. Finally, iA Global Asset Management Inc. grew its stake in shares of Gilead Sciences by 14.5% in the third quarter. iA Global Asset Management Inc. now owns 175,067 shares of the biopharmaceutical company's stock valued at $14,678,000 after buying an additional 22,228 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Trading Down 0.6 %

Shares of GILD stock traded down $0.52 during trading hours on Friday, reaching $91.86. The company had a trading volume of 7,514,582 shares, compared to its average volume of 7,068,425. The firm has a market cap of $114.48 billion, a price-to-earnings ratio of 1,026.44, a P/E/G ratio of 2.38 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The company has a 50 day moving average of $89.82 and a 200 day moving average of $79.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analysts' expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company's revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.29 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 4.35 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.35%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences's payout ratio is 3,422.22%.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Robert W. Baird increased their price target on Gilead Sciences from $80.00 to $95.00 and gave the company a "neutral" rating in a report on Thursday, November 7th. Piper Sandler raised their target price on Gilead Sciences from $95.00 to $105.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. Sanford C. Bernstein initiated coverage on Gilead Sciences in a research report on Thursday, October 17th. They set an "outperform" rating and a $105.00 price target on the stock. Mizuho raised their target price on Gilead Sciences from $90.00 to $100.00 and gave the stock an "outperform" rating in a research report on Thursday, November 21st. Finally, Citigroup began coverage on Gilead Sciences in a report on Thursday, November 14th. They set a "buy" rating and a $125.00 target price on the stock. Twelve analysts have rated the stock with a hold rating, twelve have assigned a buy rating and four have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $96.43.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now owns 100,189 shares of the company's stock, valued at $8,398,843.87. The trade was a 1.96 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 447,234 shares of company stock worth $41,288,086 in the last quarter. Corporate insiders own 0.16% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.